Title: Sustained efficacy in relapsing remitting multiple sclerosis (RRMS) following switch to placebo treatment from Cladribine Tablets 3.5 mg/kg (CT3.5) in patients with high disease activity (HDA) at baseline

Short Title: Sustained efficacy during CLARITY Extension

Main author: P. Vermersch

Additional authors: G. Giovannoni, P. Soelberg-Sørensen, B. Keller, H. Salloukh

Introduction: In CLARITY, CT3.5 showed efficacy vs placebo (PBO) over 2 years in patients with RRMS; efficacy was sustained in Years3/4 without further treatment (CLARITY Ext). In CLARITY, patients with HDA had improved/comparable clinical and magnetic resonance imaging (MRI) responses to CT3.5 than the overall CLARITY population.

Objectives: Post hoc analysis to determine if efficacy in patients with HDA, treated with CT3.5 in CLARITY (Years1/2) was sustained long-term in PBO patients in CLARITY Ext (Years3/4).

Methods: Two HDA criteria were used: 1. High relapse activity (HRA): ≥2 relapses during year before study entry whether on disease modifying drug (DMD) treatment or not; 2. HRA plus disease activity on treatment (DAT): ≥1 relapse during year before study entry while on other DMD treatment AND ≥1 T1 gadolinium-enhancing (Gd+) or ≥9 T2 lesions. Clinical and MRI outcomes were analysed for patients (N=806) randomised to CLARITY Ext who fulfilled HRA and HRA+DAT criteria at CLARITY baseline and received CT3.5 in CLARITY and PBO in CLARITY Ext.

Results: In CLARITY Ext, annualised relapse rate (ARR) of qualifying relapses for patients switched from CT3.5 in CLARITY to PBO in Ext (N=98) was 0.15 (95% confidence interval[CI]; 0.11, 0.21). ARRs for HRA(N=29) and non-HRA(N=69) were 0.15 (95%CI; 0.08, 0.28) and 0.15 (95%CI; 0.10, 0.22). For HRA+DAT(N=31) and non-HRA+DAT(N=67), ARRs were 0.14 (95%CI; 0.08, 0.26) and 0.15 (95%CI; 0.10, 0.22). ARRs were similar to the HDA subgroups in CLARITY. Fewer patients with HDA had
confirmed 3-month Expanded Disability Status Scale (EDSS) progression relative to non-HDA and overall groups (overall: 18%; HRA and non-HRA: 14% and 20%; HRA+DAT and non-HRA+DAT: 13% and 21%). The proportion of patients with confirmed 3- and 6-month EDSS progression was lower in HDA subgroups in CLARITY Ext vs CLARITY.

Conclusions: In CLARITY Ext, the clinical effect in HDA patients treated with CT3.5 in CLARITY was sustained long-term.

CLARITY: NCT00213135; CLARITY Extension: NCT00641537

Disclosures: This study was sponsored by EMD Serono Inc, a business of Merck KGaA, Darmstadt, Germany (in the USA), and Merck Serono SA, Geneva, an affiliate of Merck KGaA Darmstadt, Germany (ROW).

Author disclosures

PV has received honoraria or consulting fees from Biogen, Sanofi-Genzyme, Bayer, Novartis, Merck, Celgene, Roche and Almirall; and research support from Biogen, Sanofi-Genzyme, Bayer, and Merck.

GG has received speaker honoraria and consulting fees from Abbvie, Actelion, Atara Bio, Almirrall, Bayer Schering Pharma, Biogen Idec, FivePrime, GlaxoSmithKline, GW Pharma, Merck, Pfizer Inc, Protein Discovery Laboratories, Teva Pharmaceutical Industries Ltd, Sanofi-Genzyme, UCB, Vertex Pharmaceuticals, Ironwood, and Novartis; and has received research support unrelated to this study from Biogen Idec, Merck, Novartis, and Ironwood.

PSS has served on advisory boards for Biogen, Merck, Novartis, Teva, MedDay Pharmaceuticals, and GSK; on steering committees or independent data monitoring boards in trials sponsored by Merck, Teva, GSK, and Novartis; has received speaker honoraria from Biogen Idec, Merck Serono, Teva, Sanofi-Aventis, Genzyme, and Novartis. His department has received research support from Biogen, Merck, Teva, Novartis, Roche, and Genzyme.

BK is an employee of Merck KGaA, Darmstadt, Germany.

HS is an employee of Merck KGaA, Darmstadt, Germany.